Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here - Heart Failure Reviews
Source : https://link.springer.com/article/10.1007/s10741-022-10244-8
Heart failure with a preserved ejection fraction (HFpEF), previously known as diastolic heart failure, was first recognized more than 50 years ago. In spite of all the advances in the...
Conclusion/Relevance: This article reviews the history of HFpEF and the problems related to its definition and diagnosis over time, and critically reviews the results of the EMPEROR-Preserved Trial in light of these.
Share
Outcomes with Empagliflozin in Heart Failure with Preserved Ejection Fraction Using DELIVER-like Endpoint Definitions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35604680/
doi: 10.1002/ejhf.2558. Online ahead of print. 1 Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin,...
Conclusion: Findings from the EMPEROR-Preserved were modestly altered when analyzed using cardiovascular trial endpoint definitions of the DELIVER trial. For the composite renal endpoint, the effect of empagliflozin became statistically significant in patients with LVEF
Share
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study: Annals of Internal Medicine: Vol 0, No 0
Source : https://www.acpjournals.org/doi/10.7326/M21-4012
Background: Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared with metformin is limited. Objective: To assess cardiovascular outcomes among adults with...
Conclusion: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.
Share
Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35610696/
doi: 10.1186/s40842-022-00142-1. 1 Internal Medicine Department, Arak University of Medical Sciences, A'lam-Al-Hoda Street, Shahid Shiroodi Street, Arak, Iran. [email protected]. 2 Internal Medicine Department, Arak University of Medical Sciences, A'lam-Al-Hoda Street,...
Conclusions: Regardless of baseline albuminuria, eGFR, or HbA1c, Empagliflozin 10 mg daily significantly reduced albuminuria at 12 weeks compared to Linagliptin 5 mg daily in patients with type 2 diabetes.
Share
Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35581935/
Heart failure with preserved ejection fraction (HFpEF) is an increasingly widespread medical condition, with excessive morbidity and mortality. Recently, for the first time in HFpEF, a reduction in the primary...
Relevance: Herein, we review different approaches to HFpEF phenotyping and present some distinct HFpEF subtypes.
Share